Ocuphire Pharma, Inc. – NASDAQ:OCUP
Ocuphire Pharma stock price monthly change
Ocuphire Pharma stock price quarterly change
Ocuphire Pharma stock price yearly change
Ocuphire Pharma key metrics
Market Cap | 31.73M |
Enterprise value | N/A |
P/E | 5.76 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 2.33 |
PEG ratio | 0.04 |
EPS | -0.48 |
Revenue | 19.01M |
EBITDA | -11.70M |
Income | -11.30M |
Revenue Q/Q | -2.17% |
Revenue Y/Y | -54.29% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -61.59% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOcuphire Pharma stock price history
Ocuphire Pharma stock forecast
Ocuphire Pharma financial statements
| Jun 2023 | 3.67M | -4.96M | -135.03% |
|---|---|---|---|
| Sep 2023 | 11.93M | 5.56M | 46.59% |
| Dec 2023 | 1.69M | -4.79M | -283.56% |
| Mar 2024 | 1.71M | -7.10M | -415.31% |
| Dec 2023 | 1.69M | -4.79M | -283.56% |
|---|---|---|---|
| Mar 2024 | 1.71M | -7.10M | -415.31% |
| Sep 2025 | 4M | -6.13M | -153.25% |
| Dec 2025 | 5M | -4.65M | -93.18% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 43465000 | 5.76M | 13.25% |
|---|---|---|---|
| Sep 2023 | 54191000 | 3.90M | 7.21% |
| Dec 2023 | 53948000 | 4.04M | 7.49% |
| Mar 2024 | 51844000 | 5.78M | 11.16% |
| Jun 2023 | 989K | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -3.00M | 0 | 5.37M |
| Dec 2023 | 4.54M | 0 | 3.60M |
| Mar 2024 | -5.71M | 0 | 2.37M |
Ocuphire Pharma alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 14 |
| Apr 2024 | 14 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
Ocuphire Pharma other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 37000 | 0 |
| May 2024 | 8500 | 0 |
| Insider | Compensation |
|---|---|
Ms. Mina Patel Sooch M.B.A., MBA (1968) Founder, Chief Executive Officer, Pres, Treasurer & Vice Chair of the Board | $112,790 |
Ms. Amy Zaremba Rabourn C.P.A., MAcc, CPA (1980) Vice President of Fin. & Principal Accounting Officer | $53,030 |
Mr. Bernhard Hoffmann M.B.A. (1956) Vice President of Corporation Devel. & Operations and Sec. | $45,010 |
-
When is Ocuphire Pharma's next earnings date?
Unfortunately, Ocuphire Pharma's (OCUP) next earnings date is currently unknown.
-
Does Ocuphire Pharma pay dividends?
No, Ocuphire Pharma does not pay dividends.
-
How much money does Ocuphire Pharma make?
Ocuphire Pharma has a market capitalization of 31.73M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 52.2% to 19.05M US dollars.
-
What is Ocuphire Pharma's stock symbol?
Ocuphire Pharma, Inc. is traded on the NASDAQ under the ticker symbol "OCUP".
-
What is Ocuphire Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ocuphire Pharma?
Shares of Ocuphire Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ocuphire Pharma's key executives?
Ocuphire Pharma's management team includes the following people:
- Ms. Mina Patel Sooch M.B.A., MBA Founder, Chief Executive Officer, Pres, Treasurer & Vice Chair of the Board(age: 57, pay: $112,790)
- Ms. Amy Zaremba Rabourn C.P.A., MAcc, CPA Vice President of Fin. & Principal Accounting Officer(age: 45, pay: $53,030)
- Mr. Bernhard Hoffmann M.B.A. Vice President of Corporation Devel. & Operations and Sec.(age: 69, pay: $45,010)
-
Is Ocuphire Pharma founder-led company?
Yes, Ocuphire Pharma is a company led by its founder Ms. Mina Patel Sooch M.B.A., MBA.
-
How many employees does Ocuphire Pharma have?
As Jul 2024, Ocuphire Pharma employs 14 workers.
-
When Ocuphire Pharma went public?
Ocuphire Pharma, Inc. is publicly traded company for more then 19 years since IPO on 10 Nov 2005.
-
What is Ocuphire Pharma's official website?
The official website for Ocuphire Pharma is ocuphire.com.
-
Where are Ocuphire Pharma's headquarters?
Ocuphire Pharma is headquartered at 37000 Grand River Avenue, Farmington Hills, MI.
-
How can i contact Ocuphire Pharma?
Ocuphire Pharma's mailing address is 37000 Grand River Avenue, Farmington Hills, MI and company can be reached via phone at +248 6 819 815.
Ocuphire Pharma company profile:
Ocuphire Pharma, Inc.
ocuphire.comNASDAQ
14
Biotechnology
Healthcare
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Farmington Hills, MI 48335
CIK: 0001228627
ISIN: US67577R1023
CUSIP: 67577R102
